Actress, writer and producer Alexandra Park, best known for her role on The Royals and Australian series Home and Away, is partnering with Medtronic Diabetes to help others living with type 1 diabetes learn more about advanced technologies that can help make life with the condition easier. New to using insulin pump technology, Alexandra spotlights how the MiniMed™ 780G system has helped her get back to doing what she loves without the constant burden of daily decision-making that diabetes management entails. 

“I struggled for years manually monitoring, tracking, and dosing insulin amid my busy life and acting schedule. I was obsessed with keeping my blood sugars in the right range. It was mentally exhausting and isolating at times,” said Alexandra. “The MiniMed™ 780G system has given me so much freedom – it takes on a lot of the work I was doing myself. It’s eye-opening to see how many corrections the system automatically delivers throughout the day to keep me in range — the best I’ve experienced since diagnosis. I can stay focused on my creativity and living my best life knowing the system has my back.”  

Soon to be seen in Season Two of the hit comedy Everyone Is Doing Great, the Australian-born actress was diagnosed at age 23 with type 1 diabetes, right before relocating from Sydney to Los Angeles and landing her breakout role on The Royals. In 2021, she authored Sugar High: The Unexpected Journey of an Inexperienced Type 1 Diabetic to help reassure others navigating the same journey of uncertainty a diabetes diagnosis introduces. Alexandra began her acting career on Home and Away, an Australian soap opera.  

“We’re thrilled to partner with Alexandra Park and are so pleased the MiniMed™ 780G system has had such a positive impact on her life,” said Que Dallara, EVP & president of Medtronic Diabetes. “Type 1 diabetes can be an incredibly lonely journey and feels relentless at times – it comes with so many ups and downs. We appreciate her transparency and willingness to share her experiences. Individuals like Alexandra show that you can thrive with the help of automated insulin delivery.”  

About the MiniMed™ 780G system: 

• The MiniMed™ 780G system is an automated insulin delivery system that combines insulin pump technology, a continuous glucose monitor (CGM) and an advanced algorithm to manage insulin delivery based on changes in CGM readings. 
• It is the only system in the world with Meal Detection™ technology* that automatically adjusts and corrects^† glucose levels every 5 minutes,^§ bringing diabetes technology one step closer to mimicking a healthy pancreas. 
• Auto corrections: If carb counts aren’t exact or you occasionally miss a meal dose — the system automatically delivers a correction dose and adjusts insulin every five-minutes to keep you in range.  
• No fingersticks² with SmartGuard™ technology: The new Guardian™ 4 sensor requires no fingersticks with SmartGuard™ technology, which means fewer interruptions throughout your day. 
• Personalized glucose targets: The only system with flexible glucose targets as low as 100 mg/dL, to more closely mirror blood sugar levels of someone without diabetes. 
• Medtronic Extended™ infusion set: Designed for up to 7 days of wear without compromising comfort³ or insulin delivery⁴. It provides the opportunity to change your CGM and infusion set simultaneously – just once per week. 

For more information, please visit www.medtronicdiabetes.com/AlexPark

About the Diabetes Business at Medtronic  
Medtronic Diabetes is on a mission to alleviate the burden of diabetes by empowering individuals to live life on their terms, with the most advanced diabetes technology and always-on support when and how they need it. We've pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront. 

About Medtronic 
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com, and follow @Medtronic on LinkedIn. 

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results. 

*Taking a bolus 15 – 20 min before a meal helps to keep blood sugar levels under control after eating.  
† Refers to auto correct, which provides bolus assistance. Can deliver all auto correction doses automatically without user interaction, feature can be turned on and off. 
§ Refers to SmartGuard™ feature. Individual results may vary  
1.American Diabetes Association Professional Practice Committee; 7. Diabetes Technology: Standards of Care in Diabetes—2024. Diabetes Care 1 January 2024; 47 (Supplement_1): S126–S144. https://doi.org/10.2337/dc24-S007 
2.Fingersticks required in manual mode & to enter smartguard. If symptoms don’t match alerts & readings, use a fingerstick. Refer to user guide. Pivotal trial participants spend avg of > 93% in SmartGuard.
3. Zhang G, et al. 986-P - Assessment of adhesive patches for an extended wear infusion set. 80th ADA International Conference, June 2020.
4. Ilany J, et al. Abstract 416 - Clinical study of a new extended wear infusion set design. 13th ATTD International Conference. February 2020.